Understanding renal physiology leads to therapeutic advances in renal disease.
作者信息
Sands Jeff M
机构信息
Emory University, Atlanta, Georgia.
出版信息
Physiology (Bethesda). 2015 May;30(3):171-2. doi: 10.1152/physiol.00005.2015.
Abstract
摘要
相似文献
1
Understanding renal physiology leads to therapeutic advances in renal disease.了解肾脏生理学有助于推动肾脏疾病治疗的进展。
Physiology (Bethesda). 2015 May;30(3):171-2. doi: 10.1152/physiol.00005.2015.
2
Molecular pathways and therapies in autosomal-dominant polycystic kidney disease.常染色体显性多囊肾病的分子途径与治疗方法
Physiology (Bethesda). 2015 May;30(3):195-207. doi: 10.1152/physiol.00032.2014.
3
KHA-CARI guideline recommendations for the diagnosis and management of autosomal dominant polycystic kidney disease.KHA-CARI常染色体显性多囊肾病诊断与管理指南建议
Nephrology (Carlton). 2016 Aug;21(8):705-16. doi: 10.1111/nep.12658.
4
What is the role of somatic mutation in autosomal dominant polycystic kidney disease?体细胞突变在常染色体显性多囊肾病中起什么作用？
J Am Soc Nephrol. 2010 Jul;21(7):1073-6. doi: 10.1681/ASN.2010030328. Epub 2010 May 20.
5
Perspectives of Gene Therapies in Autosomal Dominant Polycystic Kidney Disease.常染色体显性多囊肾病的基因治疗前景
Curr Gene Ther. 2017;17(1):43-49. doi: 10.2174/1566523217666170510152808.
6
KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetic Testing for Diagnosis.KHA-CARI常染色体显性多囊肾病指南：用于诊断的基因检测
Semin Nephrol. 2015 Nov;35(6):545-549.e2. doi: 10.1016/j.semnephrol.2015.10.007.
7
Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease.常染色体显性遗传性多囊肾病的遗传机制和信号通路。
J Clin Invest. 2014 Jun;124(6):2315-24. doi: 10.1172/JCI72272. Epub 2014 Jun 2.
8
[Recent advances in studies on autosomal dominant adult polycystic kidney disease].[常染色体显性遗传性成人多囊肾病的研究新进展]
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010 Aug;27(4):402-5. doi: 10.3760/cma.j.issn.1003-9406.2010.04.009.
9
[Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease].[常染色体显性多囊肾病中的治疗性mTOR抑制]
Med Sci (Paris). 2011 Mar;27(3):249-51. doi: 10.1051/medsci/2011273249. Epub 2011 Mar 30.
10
Autosomal dominant polycystic kidney disease: the last 3 years.常染色体显性多囊肾病：过去三年
Kidney Int. 2009 Jul;76(2):149-68. doi: 10.1038/ki.2009.128. Epub 2009 May 20.
引用本文的文献
1
Phosphatase inhibition increases AQP2 accumulation in the rat IMCD apical plasma membrane.磷酸酶抑制作用可增加大鼠内髓集合管顶端质膜中 aquaporin-2（水通道蛋白 2）的积聚。
Am J Physiol Renal Physiol. 2016 Dec 1;311(6):F1189-F1197. doi: 10.1152/ajprenal.00150.2016. Epub 2016 Aug 3.
本文引用的文献
1
Molecular pathways and therapies in autosomal-dominant polycystic kidney disease.常染色体显性多囊肾病的分子途径与治疗方法
Physiology (Bethesda). 2015 May;30(3):195-207. doi: 10.1152/physiol.00032.2014.
2
The kidney research national dialogue: gearing up to move forward.肾脏研究全国对话：准备好向前迈进。
Clin J Am Soc Nephrol. 2014 Oct 7;9(10):1806-11. doi: 10.2215/CJN.07310714. Epub 2014 Sep 15.
3
Ubiquitylation and control of renal Na+ balance and blood pressure.泛素化与肾脏钠平衡和血压的调控。
Physiology (Bethesda). 2014 Jan;29(1):16-26. doi: 10.1152/physiol.00021.2013.
4
Defining kidney biology to understand renal disease.定义肾脏生物学以了解肾脏疾病。
Clin J Am Soc Nephrol. 2014 Apr;9(4):809-11. doi: 10.2215/CJN.10851013. Epub 2013 Dec 26.
5
Advances in understanding the urine-concentrating mechanism.尿液浓缩机制的研究进展。
Annu Rev Physiol. 2014;76:387-409. doi: 10.1146/annurev-physiol-021113-170350. Epub 2013 Nov 13.
6
The WNK/SPAK and IRBIT/PP1 pathways in epithelial fluid and electrolyte transport.WNK/SPAK 和 IRBIT/PP1 通路在上皮液和电解质转运中的作用。
Physiology (Bethesda). 2012 Oct;27(5):291-9. doi: 10.1152/physiol.00028.2012.
7
Everolimus in patients with autosomal dominant polycystic kidney disease.依维莫司治疗常染色体显性遗传多囊肾病。
N Engl J Med. 2010 Aug 26;363(9):830-40. doi: 10.1056/NEJMoa1003491. Epub 2010 Jun 26.
8
Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.西罗莫司与常染色体显性多囊肾病的肾脏生长。
N Engl J Med. 2010 Aug 26;363(9):820-9. doi: 10.1056/NEJMoa0907419. Epub 2010 Jun 26.
9
A physiological view of the primary cilium.初级纤毛的生理学观点。
Annu Rev Physiol. 2005;67:515-29. doi: 10.1146/annurev.physiol.67.040403.101353.
Zotero 插件